AMR Alliance Japan (Secretariat: Health and Global Policy Institute) held a meeting to discuss its FY2023 plans among Alliance members.

 AMR Alliance Japan, as an independent platform for multisector discussion with the mission of contributing to the improvement of public health by promoting measures on AMR, will continue to work with Alliance members and partner organizations to deepen policy debate around AMR.

■Overview

Date and time: Thursday, February 2, 2023
Organizer: AMR Alliance Japan (Secretariat: HGPI)

 

■Discussion

Participants (Titles omitted; in no particular order)

Kazuyuki Akai (Director, Business Development, Nippon Becton Dickinson Company Ltd.)
Hiroshi Itoh (Internal Medicine, Medical Affairs, Pfizer Japan Inc.)
Rie Ueno (BioMérieux Japan Ltd, Director Medical Affairs)
Kazunobu Ouchi (President, Japanese Society for Pediatric Infectious Diseases / Specially Appointed Professor, Department of Medical Welfare for Children, Faculty of Health and Welfare, Kawasaki University of Medical Welfare / Specially Appointed Manager, Kawasaki Medical School General Medical Center / Professor emeritus, Kawasaki Medical School)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Katsunori Kanazawa (Officer Infectious Diseases, Medical Information, Sumitomo Pharma Co., Ltd.)
Satoshi Kamayachi (Executive Board Member, Japan Medical Association)
Takashi Kitahara (Chairman, Japan Pharmaceutical Association / Professor, Department of Clinical Pharmacology, Yamaguchi University)
Takuko Sawada (Director of the Board, Executive Vice President, Shionogi & Co., Ltd.)
Hayato Shishido (Manager, Business Development Department, Research & Development Division, NISSUI PHARMACEUTICAL CO., LTD)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Mitsuru Sugawara (President, Japanese Society of Therapeutic Drug Monitoring / Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
Yoshisaburo Takahashi (General Manager, Vaccine/Infections Dept., Meiji Seika Pharma Co., Ltd.)
Hiroshi Taki (Manager, Policy & Public Affairs, Pfizer Japan Inc.)
Kazuhiro Tateda (Chairman, the Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, AMR Incentives and Advocacy TF, Japan Pharmaceutical Manufacturers Association)
Mitsuaki Nagasawa (Vice-president, Japanese Association of Medical Technologists)
Testuya Matsumoto (President, Japanese Society of Chemotherapy / President, Japanese society for clinical microbiology / Chief Professor, Department of Infectious Diseases, International University of Health and Welfare Graduate School of Medicine)
Megumi Maruyama (Global Health Officer, Sumitomo Pharma Co., Ltd.)
Yuichi Muraki (Representative, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University)
Akira Yuasa (Senior Manager, HTA/HEOR, Corporate Affairs, Health & Value, Pfizer Japan Inc.)
Masaki Yoshida (President, Japanese Society for Infection Prevention and Control)
Hiroshi Yotsuyanagi (President, Japanese Association for Infectious Diseases / Director, IMUST Hospital, Institute of Medical Science, University of Tokyo)

Moderator:

Yui Kohno (Manager, Health and Global Policy Institute)